We examined 55 consecutive patients successfully treated with primary percutaneous coronary intervention (PCI) for a first acute myocardial infarction with left ventricular (LV) systolic dysfunction. In all patients we performed echocardiographic examination, dosage of plasma brain natriuretic peptide, serum carboxy-terminal propeptide and telopeptide of procollagen type I and amino-terminal propeptide of procollagen type III at days 1 and 3, and at 1 and 6 months after index infarction. The hypertensive patients (group 1; n ¼ 30) differed for higher baseline blood pressure (133±4 mm Hg vs 118±4 mm Hg; P ¼ 0.03), greater LV mass index (108 ± 5 vs 94 ± 4 g m À2 , P ¼ 0.03) and lower mitral E/A wave peak (0.8 ± 0.06 vs 1.1±0.12, P ¼ 0.02) with respect to non-hypertensive patients (group 2; n ¼ 25). From day 1 to month 6 carboxy-terminal propeptide of procollagen type I and amino-terminal propeptide of procollagen type III increased (Po0.005 and Po0.05, respectively) in both groups, whereas carboxy-terminal telopeptide of procollagen type I increased from day 1 to day 3 (Po0.01 in both groups, respectively) and then decreased from day 3 to month 6 (Po0.01 and Po0.05 in both groups, respectively). From day 1, brain natriuretic peptide decreased in both groups (Po0.005). There was no significant difference between the two groups in values of procollagens and natriuretic peptide. Finally, LV diastolic volume and function at 6 months were similar in the two groups. Thus, in patients with reperfused acute myocardial infarction and LV dysfunction, antecedent hypertension was not associated with a different pattern of serum procollagen release and ventricular remodelling at 6 months of follow-up.
Introduction
The adverse changes in left ventricular (LV) structure and geometry which occur after myocardial infarction have been called ventricular remodelling. This remodelling process can give rise to LV dysfunction and progressive heart failure. 1 Although the mechanisms of post-myocardial infarction remodelling are multifactorial, it has now been established that changes in the extracellular collagen matrix (ECCM) contribute greatly to LV remodelling. 2 Systemic arterial hypertension causes significant alteration in cardiac geometry and function, 3 as well as in the ECCM composition. 4 Antecedent hypertension increases the risk of heart failure after acute myocardial infarction (AMI). 5, 6 The progression of heart failure after AMI is mainly related to LV remodelling; 1 however, whether hypertension contributes directly to the post-infarction remodelling process has not yet been defined. Studies evaluating the relation between hypertension and LV remodelling in patients after AMI with LV systolic dysfunction have yielded conflicting results 6, 7 and, to date, no data have been presented on the relationship between antecedent hypertension and ECCM remodelling after AMI.
The non-invasive monitoring of collagen turnover using serologic markers related to its synthesis and degradation has been validated in the clinical setting of AMI [8] [9] [10] and of hypertensive heart disease.
11-14 Accordingly, we serially measured serum products collagen types I and III turnover, which constitute the bulk of cardiac ECCM, 15 and LV volumes and function in a consecutive sample of patients successfully treated with primary percuta-neous coronary intervention (PCI) for a first AMI with LV systolic dysfunction. The purpose of this study was to evaluate if a different pattern of ECCM and LV remodelling is present in patients with antecedent hypertension compared with those without hypertension.
Materials and Methods
Study patients and protocol A total of 65 patients, selected among 211 patients consecutively referred for emergency primary PCI, were enroled according to the following inclusion criteria: (1) confirmed first ST-elevation AMI with LV systolic dysfunction (LV ejection fraction (LVEF) p40%) and (2) successful primary PCI (defined as thrombolysis in myocardial infarction (TIMI) grade 3 flow and residual stenosis o30%). Exclusion criteria were (1) cardiogenic shock, (2) other noncoronary cardiac disease, (3) renal insufficiency (serum creatinine 42.0 mg dl À1 ), (4) diseases potentially responsible for abnormal collagen turnover (alcoholic liver disease, metabolic bone disease, hyperthyroidism, pulmonary fibrosis and connective tissue disorders), (5) life-limiting non-cardiac disease and (6) inadequate echocardiographic image quality. Of the 65 patients eligible for the study, two (3%) were excluded for lack of adherence to the protocol. During the 6-month follow-up, eight patients (four hypertensive (13%) and four nonhypertensive (16%), P ¼ NS) died (six from refractory congestive heart failure and two suddenly). Thus, the final study group consists of 55 patients. All patients underwent serial follow-up including clinical status, echocardiography and dosage of plasma brain natriuretic peptide (BNP), carboxyterminal propeptide of procollagen type I (PICP), carboxy-terminal telopeptide of procollagen type I (ICTP) and amino-terminal propeptide of procollagen type III (PIIINP) at days 1 and 3, and 1 and 6 months after the index AMI. Furthermore, 6 months after AMI, coronary angiography was performed for the evaluation of infarct-related artery patency. The Ethics Committee of our institution approved the study protocol and all patients gave written informed consent to participate in the study.
Echocardiography
Complete M-mode and two-dimensional echocardiography and Doppler ultrasound examinations were performed with a commercially available imaging system (Hewlett Packard Sonos 5500, Andover, MA, USA). Details pertaining to acquisition and analysis of echocardiographic data have been reported elsewhere. 16 Measurement of BNP and indices of collagen metabolism Blood samples were taken at least 30 min before sampling, with the patient resting in semi-recumbent supine position. For BNP, blood samples were collected into ethylene diamine tetra acetic acid and aprotinin (500 KIU ml À1 ) plastic tubes; plasma was separated by centrifugation 2000 g at 4 1C and stored at À80 1C until analysis. Plasma BNP was measured by a commercial IRMA method (Shionoria BNP, CIS-Bio International, Milan, Italy). Minimum sensitivity and upper limit of the normal values were 2 and 18.4 pg ml À1 for the BNP assay, with the highest intra-and inter-assay coefficients of variation being 2.7 and 4.2%. For PICP, ICTP and PIIINP blood samples were collected into plastic tubes without additives and the separated sera were stored at À80 1C until analysis. PICP, ICTP and PIIINP were measured by radioimmunoassay kits (Orion Diagnostica, Espoo, Finland). Minimum sensitivity and upper limit of the normal values were 1.2 and 202 ng ml À1 for the PICP assay, 0.4 and 5.6 ng ml
À1
for the ICTP assay and 0.2 and 4.5 ng ml À1 for PIIINP respectively. The highest intra-and inter-assay coefficients of variation were 3.2 and 6.6% for the PICP, 9.4 and 9.0% for the ICTP and 1.7 and 5.3% for the PIIINP.
Definitions and outcome measures
Patients were categorized as having antecedent hypertension if this diagnosis was known by the patient to have been made by the family physician or after specialist referral and/or the admission note indicated a history of hypertension. 6 LV systolic dysfunction was defined as an echocardiographic LVEF p40%. 16 A restrictive LV filling pattern was defined as a Doppler mitral E wave deceleration time (DT) p130 ms. 17 Coronary restenosis was defined as a X50% diameter stenosis of the infarct-related artery at follow-up angiogram.
Statistical analysis
Continuous data were expressed as mean ± s.d.; categorical data were expressed as frequencies. Continuous variables were tested by unpaired t-test once normality was demonstrated (Shapiro-Wilks test); otherwise, a non-parametric test was used (Mann-Whitney U-Test). Categorical variables were compared by the Fisher's exact test. ANOVA with the Bonferroni post-hoc test and Friedman ANOVA were used to analyze changes in echocardiographic measures (LV volumes, LVEF and deceleration time of early transmitral flow-DT) and neurohormonal measures (BNP, ICTP, PICP and PIIINP) over time, respectively. Univariate and multivariate linear regression analyses were performed to examine the association between the total (S) serum molar [PICP/ ICTP] ratio or PIIINP (as an index of the equilibrium between collagen type I and type III metabolism, respectively), and medical therapy, 6-month echocardiographic variables expressive of LV remodelling (left ventricular end diastolic index (LVEDVI), left ventricular end systolic index (LVESVI), LVEF, LV wall motion score index (LVWMSI), interventricular and posterior LV wall thickness, restrictive LV filling pattern, mitral E velocity and mitral A velocity (E/A) ratio, left atrial diameter). Models were adjusted for enzymatic infarct size (CK peak), which is the principal driver of the LV remodelling process. A P-value of o0.05 was considered statistically significant. All statistical calculations were performed by SPSS for Windows (release 11.5).
Results
Baseline clinical and echocardiographic characteristics and angiographic follow-up Of the 55 selected patients, 30 (55%) were classified as having antecedent hypertension. The mean duration of hypertension was 7.9 years±0.9. The baseline clinical, echocardiographic and angiographic, characteristics of patients with antecedent hypertension (group 1, n ¼ 30) and without antecedent hypertension (group 2, n ¼ 25) are shown in Table 1 . The hypertensive group had significantly higher baseline blood pressure (133 ± 24 mm Hg vs 118±22 mm Hg; P ¼ 0.03), greater interventricular septal (1.15 ± 0.05 cm vs 0.97 ± 0.18 cm, Po0.001) and posterior LV wall thickness (1.18±0.06 cm vs 0.91±0.15 cm, Po0.001), LV mass index (108±30 vs 94 ± 21 g m À2 , P ¼ 0.03) and left atrial diameter (3.8±0.3 vs 3.4±0.6 cm, P ¼ 0.01) than non-hypertensive patients. Furthermore, the significantly lower values of E/A ratio (0.8 ± 0.4 vs 1.1 ± 0.6, P ¼ 0.02) and the trend towards significantly higher values of DT (183±55 vs 155±57 ms, P ¼ 0.05) observed in the hypertensive group, suggest that this group of patients may have demonstrable evidence of hypertensive heart disease. There were no other significant differences between the two study groups.
The angiographic follow-up rate was 100%. The infarct-related artery patency rate was 100% in both groups.
Medical therapy
Medical therapy at Hospital discharge and at 6-month follow-up is shown in Table 2 . At discharge there was no significant difference between the two groups. During follow-up, a significant increase in the use of b-blockers in both groups of patients (group 1: from 20 to 50%, P ¼ 0.01; group 2: from 20 to 40%, P ¼ 0.03) and in the use of statins in group 2 (from 68 to 92%, P ¼ 0.04) was observed. Furthermore, in patients with and without antecedent hypertension the use of diuretics and aldosterone antagonists were reduced during follow-up, even if this did not reach statistical significance. However, similarly, at hospital discharge after 6 months, there were no significant differences in medical therapy between the two groups.
Serial changes in serum products of collagen types I and III Serial changes in serum products of collagen types I and III are shown in Figures 1 and 2 , respectively. In both study groups, PICP increased progressively and significantly from day 1 to month 6 (group 1: from 103±31 to 140±54 mg l À1 , Po0.005; group 2: from 89±31 to 144±44 mg l À1 , Po0.005). ICTP significantly increased from day 1 to day 3 (group 1: from 5.7 ± 3.3 ng ml À1 to 6.3 ± 3.3 ng ml À1 , group 2: from 4.6±1.7 ng ml À1 to 5.9±2.3 ng ml À1 , Po0.01 for both groups, respectively) and then decreased from day 3 to 6 months (group 1: 4.8 ± 2.1 ng ml À1 , Po0.01 group 2: 4.8±1.7 ng ml À1 ; Po0.05). Overall, the time course of [PICP/ICTP], as an index of coupling between synthesis and degradation of collagen type I, was similar in both groups. It decreased transiently from day 1 to day 3 (group 1: from 2.4±1.8 to Collagen turnover after infarction in hypertensives G Cerisano et al 2.1 ± 1.4, P ¼ 0.649; group 2: from 2.2 ± 1.1 to 2.0 ± 1.0, P ¼ 0.45) and increased significantly thereafter up to 6 months (group 1: from 2.1±1.4 to 3.5 ± 2.2; group 2: from 2.2 ± 1.1 to 3.4 ± 1.8, Po0.01 for both groups, respectively). Serum PIIINP increased significantly, from day 1 to 6 months, similarly in both groups of patients (group 1: from 3.3 ± 1.2 to 3.9 ± 1.9 ng ml À1 ; group 2: from 2.8 ± 1.1to 3.4±1.3 ng ml À1 , Po0.05 for both groups, respectively). At each point during the entire follow-up, there was no significant difference between the two groups in PICP, ICTP, [PICP/ICTP] and PIIINP.
Serial changes in BNP Serial changes in plasma BNP are shown in Figure 3 . In both groups of patients, BNP progressively and significantly decreased from day 1 to month 6 (group 1: from 241±194 to 101±118 pg ml À1 ; group 2: from 219 ± 170 to 125 ± 155 pg ml À1 , Po0.005
for both groups, respectively), without significant difference between the two groups at each time point of measurement.
Serial changes in echocardiographic LV volumes and function
In both groups of patients, from day 1 to month 6, LVESVI did not change significantly (group 1: from 37±8 to 35±13 ml m À2 , P ¼ 0.066; group 2: from 36±10 to 38±18 ml m À2 , P ¼ 0.241), whereas LVED-VI (group 1: from 58 ± 12 to 65 ± 17 ml m À2 , P ¼ 0.03; group 2: from 56 ± 12 to 68 ± 21 ml m À2 , P ¼ 0.001) and LVEF (group 1: from 35±5 to 47±11, Po0.001; group 2: from 34 ± 7 to 45 ± 13, Po0.001) increased significantly. Moreover, at each time point, there was no significant difference between the two groups in LV volumes and LVEF. Posterior LV wall thickness did not change in both groups (group 1: from 1.18±0.06 to 1.20±0.07 cm, P ¼ 0.14; group 2: from 0.91 ± 0.1 to 0.84 ± 0.1 cm, P ¼ 0.11). Interventricular septal thickness did not change in group 1 (from 1.15±0.05 to 1.14±0.08 cm, P ¼ 0.53), whereas it decreased significantly in group 2 (from 0.97 ± 0.18 to 0.84 ± 0.14 cm, P ¼ 0.005). Relative to LV diastolic function, we observed that DT increased significantly in both groups of patients (group 1: from 155 ± 57 to 213 ± 67 ms, Po0.001; group 2: from 183 ± 55 to 220 ± 42 ms, Po0.001). Mitral E velocity and mitral A velocity (E/A) ratio increased in group 1 but not in group 2 (group 1: from 0.78 ± 0.4 to 0.95 ± 0.5, P ¼ 0.005; group 2: from 1.1±0.6 to 1.1±0.6, P ¼ 0.78), so that at month 6 there were no more differences between two groups. Isovolumic relaxation time (IVRT) was unchanged in both groups (group 1: from 113±33 to 110±20 ms, P ¼ 0.88; group 2: from 115±32 to 109 ± 19 ms, P ¼ 0.92). LV restrictive filling pattern rate was 6.6% and 8% in groups 1 and 2, respectively (P ¼ 0.85). Table 3 shows the univariate and multivariate association between S [PICP/ICTP] and some echocardiographic parameters of LV systolic and diastolic function at 6-month follow-up, as well as in medical therapy. At stepwise multivariate analysis S [PICP/ICTP] was independently associated with LVEDVI, LV restrictive filling pattern and therapy with loop diuretic. In contrast, no significant association was found with S PIIINP.
Univariate and multivariate regression analysis

Discussion
The main finding of this study is that, in patients with AMI and LV dysfunction successfully treated with primary PCI, antecedent hypertension was not associated with a different pattern of ECCM remodelling, as assessed by non-invasive monitoring of serologic markers related to its synthesis and Several studies have demonstrated that arterial hypertension induces interstitial alterations characterized by an increase of collagen synthesis. [11] [12] [13] [14] This excess of myocardial collagen is primarily a result of the uncoupling between increased synthesis and unchanged or decreased degradation of collagen type I fibres. 18 However, patients with coronary heart disease have been excluded from these studies, 11-14 so it is not clear if a different pattern of interstitial remodelling may be present in the first months after AMI in patients with antecedent hypertension.
The prevalence of antecedent hypertension observed in this study is higher than previously reported, 6 likely because of the higher risk profile of AMI patients. Consistently, it matches the result observed in the Valsartan in Acute Myocardial Infarction (VALIANT) trial. 19 Time course of serum PICP, ICTP and [PICP/ICTP], as an index of the equilibrium between collagen type I synthesis and degradation, was substantially similar in patients with and without antecedent hypertension throughout the 6-month post-AMI period. In this context, the biphasic pattern of serum [PICP/ICTP] mirrors the time-dependent changes in the ratio between metalloproteinase-9, which plays an important role in collagen breakdown early after AMI, and its inhibitors-4 observed in post-infarction patients. 20 Serum PIIINP, which may reflect both synthesis and degradation of type III collagen in AMI patients, 21, 22 increased significantly from baseline to 6 months. In addition, these changes were similar in the 2 groups of patients throughout the 6-month post-AMI period.
Of note, at multivariate regression analysis we found a significant inverse association-adjusted for the enzymatic infarct size-between S serum [PICP/ ICTP] and 6-month LVEDVI and LV restrictive filling pattern, perhaps consistent with the premise that changes in the ECCM could contribute greatly to LV remodelling. 2 In contrast, we did not observe any relationship between S serum PIIINP and echocardiographic parameters; this result cannot be elucidated from this study. However, it is at odds with recent reports from the Framingham Heart Study. 23 On the whole, these results are consistent with experimental and clinical studies demonstrating that a shift in ECCM remodelling towards greater degradation is related to post-AMI LV dilation. [24] [25] [26] We observed also that the S serum [PICP/ICTP] resulted inversely related to loop diuretic therapy. This is an interesting finding in this clinical setting, consistent with previous data on heart failure patients reporting that torasemidetreated patients exhibited a reduction of myocardial collagen accumulation and a diminution of collagen type I synthesis. 27 In conclusion, in this study based on patients with AMI and LV dysfunction successfully treated with primary PCI, we observed that the pattern of release of serum products of collagen types I and III metabolism, or the time course of BNP activation throughout the 6-month post-AMI period or the propensity for LV remodelling in terms of LV dilation and dysfunction 6 months after AMI, was similar in patients with and without antecedent hypertension. It is possible that the extent of reparative and adaptive post-AMI processes, which occur after an AMI with resultant LV systolic dysfunction, was sufficient to blunt the differences related to hypertensive status itself.
Clinical implications
Although the weight of evidence indicates an adverse effect of antecedent hypertension on heart failure after AMI, 5, 6 whether (and in which patients) it is related to a greater propensity of hypertensive patients to develop LV remodeling, is disputed. 6, 7 In this context some findings reported here may be of clinical interest. During the first 6 months after a reperfused AMI with LV systolic dysfunction there were no differences between patients with and without antecedent hypertension in LV remodelling processes, as assessed by the time course of serum products of collagen types I and III metabolism, plasma BNP and echocardiographic indices of LV geometry/function, respectively. A number of effects of chronic hypertension (and associated greater LV mass), other than LV remodelling, may predispose to an adverse outcome after AMI. A decreased coronary flow reserve, 28 and an abnormal ventricular-arterial interaction due to stiffening of both systems 29 may contribute to heart failure pathophysiology in these patients, by reducing tolerance of myocardial ischaemia, limiting mechanisms of cardiovascular reserve, exacerbating diastolic abnormalities and potentially raising cardiac energy demand. These aspects should be considered while developing new therapeutic strategies.
Limitations
The relatively small number of patients may represent a study limitation. However we were able to reach several significant observations. It must be recognized that therapy with different types of drugs may have confounded the findings and their interpretation. Nevertheless, there were no differences in the distribution of the different types of drugs between the two groups of patients. Finally, this study included only patients successfully treated with early primary PCI for a first ST-segment elevation myocardial infarction with LV systolic dysfunction. Whether our results can be extrapolated to a larger population with AMI remains to be seen.
